闭环治疗与1型糖尿病C肽分泌的保留
该多中心、开放标签、平行组随机试验纳入97例新诊断1型糖尿病青少年(平均年龄12±2岁),在诊断后21天内随机接受混合闭环治疗(51例)或标准胰岛素治疗(46例),持续24个月。主要终点为诊断后12个月混合餐耐量试验血浆C肽曲线下面积,两组无显著差异(几何均值0.35 vs 0.46 pmol/mL;校正均差-0.06 pmol/mL,95%CI -0.14至0.03)。24个月C肽AUC亦无显著差异(0.18 vs 0.24 pmol/mL;校正均差-0.04 pmol/mL,95%CI -0.14至0.06)。闭环组糖化血红蛋白在12个月和24个月分别较对照组低4 mmol/mol(0.4个百分点)和11 mmol/mol(1.0个百分点)。结论提示强化血糖控制24个月似乎未能阻止残余C肽分泌下降。
要点
- 新发1型糖尿病青少年(10.0-16.9岁,诊断后21天内)随机接受混合闭环或标准胰岛素治疗24个月。
- 12个月C肽AUC几何均值闭环组0.35 pmol/mL vs 对照组0.46 pmol/mL,校正均差-0.06 pmol/mL(95%CI -0.14至0.03),无显著差异。
- 24个月C肽AUC几何均值闭环组0.18 pmol/mL vs 对照组0.24 pmol/mL,校正均差-0.04 pmol/mL(95%CI -0.14至0.06),无显著差异。
- 糖化血红蛋白闭环组较对照组12个月低4 mmol/mol(0.4个百分点;95%CI 0至8 mmol/mol),24个月低11 mmol/mol(1.0个百分点;95%CI 7至15 mmol/mol)。
- 闭环组发生5例严重低血糖(3例参与者),对照组1例;闭环组发生1例糖尿病酮症酸中毒。
适用人群与场景
- 10.0至16.9岁、诊断1型糖尿病后21天内的青少年,来自多中心随机试验。
处置流程与药物剂量
- 混合闭环治疗或标准胰岛素治疗,持续24个月。
研究设计与关键结果
- 多中心、开放标签、平行组随机试验,97例参与者随机(闭环组51例,对照组46例),平均年龄12±2岁。
- 主要终点12个月C肽AUC几何均值:闭环组0.35 pmol/mL(四分位距0.16至0.49)vs 对照组0.46 pmol/mL(0.22至0.69),校正均差-0.06 pmol/mL(95%CI -0.14至0.03),无显著差异。
- 24个月C肽AUC几何均值:闭环组0.18 pmol/mL(四分位距0.06至0.22)vs 对照组0.24 pmol/mL(0.05至0.30),校正均差-0.04 pmol/mL(95%CI -0.14至0.06)。
- 糖化血红蛋白算术均值:12个月闭环组较对照组低4 mmol/mol(0.4个百分点;95%CI 0至8 mmol/mol [0.0至0.7个百分点]),24个月低11 mmol/mol(1.0个百分点;95%CI 7至15 mmol/mol [0.5至1.5个百分点])。
- 严重低血糖:闭环组5例(发生于3例参与者),对照组1例;糖尿病酮症酸中毒:闭环组1例。
证据类型、等级与局限
- 随机对照试验(多中心、开放标签、平行组),意向性治疗分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于新发1型糖尿病青少年,混合闭环治疗可降低糖化血红蛋白,但似乎未能保留C肽分泌。
- 作者认为,在新发1型糖尿病青少年中,24个月的强化血糖控制似乎未能阻止残余C肽分泌的下降。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether improved glucose control with hybrid closed-loop therapy can preserve C-peptide secretion as compared with standard insulin therapy in persons with new-onset type 1 diabetes is unclear.
METHODS: In a multicenter, open-label, parallel-group, randomized trial, we assigned youths 10.0 to 16.9 years of age within 21 days after a diagnosis of type 1 diabetes to receive hybrid closed-loop therapy or standard insulin therapy (control) for 24 months. The primary end point was the area under the curve (AUC) for the plasma C-peptide level (after a mixed-meal tolerance test) at 12 months after diagnosis. The analysis was performed on an intention-to-treat basis.
RESULTS: A total of 97 participants (mean [±SD] age, 12±2 years) underwent randomization: 51 were assigned to receive closed-loop therapy and 46 to receive control therapy. The AUC for the C-peptide level at 12 months (primary end point) did not differ significantly between the two groups (geometric mean, 0.35 pmol per milliliter [interquartile range, 0.16 to 0.49] with closed-loop therapy and 0.46 pmol per milliliter [interquartile range, 0.22 to 0.69] with control therapy; mean adjusted difference, -0.06 pmol per milliliter [95% confidence interval {CI}, -0.14 to 0.03]). There was not a substantial between-group difference in the AUC for the C-peptide level at 24 months (geometric mean, 0.18 pmol per milliliter [interquartile range, 0.06 to 0.22] with closed-loop therapy and 0.24 pmol per milliliter [interquartile range, 0.05 to 0.30] with control therapy; mean adjusted difference, -0.04 pmol per milliliter [95% CI, -0.14 to 0.06]). The arithmetic mean glycated hemoglobin level was lower in the closed-loop group than in the control group by 4 mmol per mole (0.4 percentage points; 95% CI, 0 to 8 mmol per mole [0.0 to 0.7 percentage points]) at 12 months and by 11 mmol per mole (1.0 percentage points; 95% CI, 7 to 15 mmol per mole [0.5 to 1.5 percentage points]) at 24 months. Five cases of severe hypoglycemia occurred in the closed-loop group (in 3 participants), and one occurred in the control group; one case of diabetic ketoacidosis occurred in the closed-loop group.
CONCLUSIONS: In youths with new-onset type 1 diabetes, intensive glucose control for 24 months did not appear to prevent the decline in residual C-peptide secretion. (Funded by the National Institute for Health and Care Research and others; CLOuD ClinicalTrials.gov number, NCT02871089.).
参考来源
- Boughton CK, Allen JM, Ware J, et al. Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes. N Engl J Med. 2022. PMID: 36069870. doi:10.1056/NEJMoa2203496
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。